Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform
Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of...
China NPC Passes Medical Security Law, Establishing Multi‑Tier Medical Insurance Framework Effective 2027
The Standing Committee of the National People’s Congress (NPC) voted to pass the Medical Security...
Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug
China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million...
WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...
Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the...
Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a...
GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
GluBio Pharmaceuticals announced that GLB‑005, its self‑developed widely interspaced zinc finger (WIZ) molecular glue degrader...
Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:...
Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...
HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for...
AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...
Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Livzon Pharmaceutical (HKG: 1513) announced that lecankitug, jointly developed with Beijing Kanova Biopharma, has been...
TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases
TYK Medicines (HKG: 2410) announced that its independently developed next-generation EGFR-TKI, asandeutertinib (TY-9591), has received...
AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease
AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency...
TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices
TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...
ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in...